DNMT1 and neoplasm: Functional inactivation of PRC2 via oncohistone mutation (H3 K27M) was also observed in pediatric gliomas [282], suggesting that it is possible to set up a tumor context-specific liability for therapeutic intervention via DNMT1 inhibitors in selective cancer types.